About us
BIGS DrugS was founded in the year 2010. It is part of the BIGS (Bonn International Graduate Schools) umbrella program for structured doctoral programs at the University of Bonn. BIGS DrugS offers talented young scientists a three-year structured PhD training program in the field of drug research related to biomedical disciplines. BIGS DrugS students work on their individual PhD research projects. In parallel they participate in the comprehensive BIGS DrugS education program that includes workshops, lectures, colloquia and symposia. Mentoring is performed by two experienced scientists, the direct PhD supervisor and a co-supervisor. BIGS DrugS aims at creating an optimal research and education environment for PhD students and provides support for a successful scientific career development.
Picture source: Volker Lannert
Research
BIGS DrugS principal investigators are interested in basic as well as applied research related to the invention of innovative drugs and therapeutic approaches. BIGS DrugS scientists investigate novel pharmacological drug targets, new chemical and biological lead compounds as potential drug candidates and develop innovative therapeutic concepts based on stem cells, RNA- or nanotechnology. The therapy of common diseases relating to the nervous and cardiovascular system as well as oncological and metabolic/gastrointestinal disorders are in the medical focus of BIGS DrugS research studies.
Picture Source: Frank Homann
Interdisciplinarity
Significant characteristics of BIGS DrugS are its strong interdisciplinary approach and cooperation across the two large faculties, the Faculty of Mathematics and Natural Sciences and the Faculty of Medicine at the University of Bonn. Experts in drug research, drug development and pharmacology from both faculties create an outstanding research environment and provide excellent education and training for PhD students. Collaboration partners from extramural institutions including relevant authorities as well as pharma and biotech industries contribute actively to the BIGS DrugS graduation program.
Picture source: Dominik Fritz
